Advertisement
Advertisement
U.S. Markets close in 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4700-0.0100 (-0.29%)
As of 03:36PM EST. Market open.
Advertisement

InflaRx N.V.

Winzerlaer Str. 2
Jena 07745
Germany
49 3641 508 180
https://www.inflarx.de

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees47

Key Executives

NameTitlePayExercisedYear Born
Dr. Niels C. Riedemann M.D., Ph.D.Co-Founder, CEO & Exec. DirectorN/AN/A1972
Prof. Renfeng GuoCo-Founder, Chief Scientific Officer & Exec. DirectorN/AN/A1970
Dr. Thomas Taapken Ph.D.Chief Financial OfficerN/AN/A1965
Mr. Jordan SilversteinHead of Corp. Devel. & StrategyN/AN/AN/A
Dr. Maria Habel PH.D.Head of Preclinical R&DN/AN/A1982
Ms. Katrin ReiherHead of Quality ManagementN/AN/A1982
Mr. Jordan ZwickChief Strategy OfficerN/AN/A1987
Dr. Korinna Pilz M.D., M.Sc.Chief Clinical Devel. OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Corporate Governance

InflaRx N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement